GlaxoSmithKline PLC Company Profile (NYSE:GSK)

About GlaxoSmithKline PLC

GlaxoSmithKline PLC logoGlaxoSmithKline plc (GSK) is a healthcare company. The Company is engaged in the creation and discovery, development, manufacture and marketing of pharmaceutical products, including vaccines, over-the-counter (OTC) medicines and health-related consumer products. The Company's segments include Pharmaceuticals, Pharmaceuticals R&D, Vaccines and Consumer Healthcare. The Pharmaceuticals business develops and makes medicines to treat a range of acute and chronic diseases. The Vaccines business develops, produces and distributes over 1.9 million vaccines every day to people across the world. The Consumer Healthcare business develops and markets products in various categories, such as Wellness, Oral health, Nutrition and Skin health. The Pharmaceuticals Research and Development (R&D) focuses on the discovery and development in various areas of research, which include human immunodeficiency virus (HIV) and infectious diseases, oncology, immuno-inflammation, respiratory and rare diseases.

Industry, Sector and Symbol:
  • Sector: Medical
  • Industry: Drug Manufacturers - Major
  • Sub-Industry: N/A
  • Exchange: NYSE
  • Symbol: GSK
  • CUSIP:
Key Metrics:
  • Previous Close: $41.56
  • 50 Day Moving Average: $39.68
  • 200 Day Moving Average: $40.69
  • 52-Week Range: $37.20 - $45.58
  • Trailing P/E Ratio: 89.96
  • Foreward P/E Ratio: 14.84
  • P/E Growth: 1.09
  • Market Cap: $101.16B
  • Outstanding Shares: 2,434,000,000
  • Beta: 0.94
  • Net Margins: 3.11%
  • Return on Equity: 100.68%
  • Return on Assets: 8.68%
  • Debt-to-Equity Ratio: 2.95%
  • Current Ratio: 0.88%
  • Quick Ratio: 0.61%
Additional Links:
Companies Related to GlaxoSmithKline PLC:

Analyst Ratings

Consensus Ratings for GlaxoSmithKline PLC (NYSE:GSK) (?)
Ratings Breakdown: 1 Sell Rating, 5 Hold Ratings, 10 Buy Ratings
Consensus Rating:Buy (Score: 2.56)
Consensus Price Target: $50.00 (20.31% upside)

Analysts' Ratings History for GlaxoSmithKline PLC (NYSE:GSK)
DateFirmActionRatingPrice TargetDetails
2/19/2017Jefferies Group LLCReiterated RatingBuyView Rating Details
2/15/2017J P Morgan Chase & CoReiterated RatingNeutralView Rating Details
2/9/2017Deutsche Bank AGReiterated RatingNeutralView Rating Details
12/27/2016Goldman Sachs Group, Inc. (The)Reiterated RatingBuyView Rating Details
11/7/2016Citigroup Inc.Reiterated RatingBuyView Rating Details
10/26/2016Beaufort SecuritiesReiterated RatingBuyView Rating Details
10/20/2016InvestecInitiated CoverageBuyView Rating Details
9/23/2016Piper Jaffray CompaniesInitiated CoverageOverweightView Rating Details
9/20/2016Bank of America CorpReiterated RatingBuy$50.00View Rating Details
9/13/2016BNP ParibasDowngradeNeutral -> UnderperformView Rating Details
9/12/2016HSBC Holdings plcReiterated RatingBuyView Rating Details
8/17/2016Shore CapitalReiterated RatingHoldView Rating Details
8/12/2016ArgusBoost Price TargetBuy$48.00 -> $50.00View Rating Details
5/26/2016Cowen and CompanyDowngradeOutperform -> Market PerformView Rating Details
5/5/2016Oddo SecuritiesUpgradeReduce -> BuyView Rating Details
2/26/2016Cantor FitzgeraldInitiated CoverageHoldView Rating Details
2/4/2016Sanford C. BernsteinBoost Price TargetMarket Perform$43.00 -> $45.00View Rating Details
1/27/2016Bryan, Garnier & CoUpgradeNeutral -> BuyView Rating Details
12/21/2015Leerink SwannReiterated RatingMarket Perform$48.00View Rating Details
11/6/2015Morgan StanleyReiterated RatingNeutralView Rating Details
10/31/2015Societe GeneraleReiterated RatingSellView Rating Details
10/20/2015Credit Suisse GroupUpgradeUnderperform -> NeutralView Rating Details
6/26/2015Liberum CapitalUpgradeSell -> HoldView Rating Details
5/22/2015Berenberg BankReiterated RatingHoldView Rating Details
4/16/2015Barclays PLCReiterated RatingOverweightView Rating Details
3/30/2015Kepler Capital MarketsReiterated RatingHoldView Rating Details
(Data available from 2/25/2015 forward)


Earnings History for GlaxoSmithKline PLC (NYSE:GSK)
DateQuarterConsensus EstimateActual EPSRevenue EstimateActual RevenueRelease LinkConference CallDetails
2/8/201712/31/2016$0.61$0.65ViewListenView Earnings Details
2/3/2016Q415$0.18$0.18$6.28 billion$6.29 billionViewN/AView Earnings Details
10/28/2015Q3$0.60$0.71$6.07 billion$6.13 billionViewN/AView Earnings Details
7/29/2015Q215$0.50$0.53ViewN/AView Earnings Details
5/6/2015Q115$0.55$0.48ViewN/AView Earnings Details
2/4/2015Q414$0.86$0.82$6.14 billion$6.19 billionViewN/AView Earnings Details
10/22/2014Q314$0.79$0.90ViewListenView Earnings Details
7/23/2014Q114$0.71$0.65ViewN/AView Earnings Details
4/30/2014Q413$0.72$0.70ViewN/AView Earnings Details
2/5/2014Q4$0.30$0.30$6.84 billion$6.91 billionViewN/AView Earnings Details
10/23/2013Q313$0.31$10.31 billion$10.09 billionViewN/AView Earnings Details
7/24/2013$0.26$0.26$6.62 billionViewN/AView Earnings Details
4/25/2012$0.29$0.27ViewN/AView Earnings Details
2/7/2012$0.30$0.28ViewN/AView Earnings Details
(Data available from 1/1/2011 forward)


Earnings Estimates for GlaxoSmithKline PLC (NYSE:GSK)
Current Year EPS Consensus Estimate: $2.77 EPS
Next Year EPS Consensus Estimate: $2.80 EPS
QuarterNumber of EstimatesLow EstimateHigh EstimateAverage Estimate
Q1 20161$0.50$0.50$0.50
Q2 20162$0.54$0.55$0.55
Q3 20162$0.72$0.78$0.75
Q4 20162$0.45$0.61$0.53
Q1 20171$0.59$0.59$0.59
Q2 20171$0.74$0.74$0.74
Q3 20171$0.83$0.83$0.83
Q4 20171$0.74$0.74$0.74
(Data provided by Zacks Investment Research)


Current Dividend Information for GlaxoSmithKline PLC (NYSE:GSK)
Annual Dividend:$1.83
Dividend Yield:4.40%
Dividend Growth:-3.10% (3 Year Average)
Payout Ratio:389.36% (Based on Trailing 12 Months of Earnings)
66.06% (Based on Current Year Consensus EPS Estimate)
65.36% (Based on Next Year Consensus EPS Estimate)

Dividend History for GlaxoSmithKline PLC (NYSE:GSK)
AnnouncedPeriodAmountYieldEx-Dividend DateRecord DatePayable Date
(Data available from 1/1/2013 forward)

Insider Trades

Insider Trading History for GlaxoSmithKline PLC (NYSE:GSK)
Insider Ownership Percentage: 10.00%
Institutional Ownership Percentage: 8.41%
Transaction DateInsider NameTitleBuy/SellNumber of SharesAverage Share PriceTotal TransactionDetails
10/24/2016Plc GlaxosmithklineMajor ShareholderBuy66,500$14.00$931,000.00View SEC Filing  
(Data available from 1/1/2013 forward)


Latest Headlines for GlaxoSmithKline PLC (NYSE:GSK)
News IconABR Of GlaxoSmithKline PLC (NYSE:GSK) At 1.86 | Stock Observer - Stock Observer (NYSE:GSK) - February 25 at 5:21 PM
News IconBetter Buy: Eli Lilly and Co vs. GlaxoSmithKline plc | Business ... - (NYSE:GSK) - February 25 at 5:21 PM logoBetter Buy: Eli Lilly and Co vs. GlaxoSmithKline plc (NYSE:GSK) - February 25 at 5:21 PM
News IconGlaxoSmithKline PLC (LON:GSK) Receives Hold Rating From Berenberg Analysts (NYSE:GSK) - February 24 at 6:50 PM logoGlaxoSmithKline Reports Positive Resultsfrom Relvar Ellipta Lung Function Study (NYSE:GSK) - February 23 at 5:32 PM
News IconGlaxoSmithKline Reports Positive Study Results for Asthma Drug (NYSE:GSK) - February 23 at 5:32 PM
News IconGlaxoSmithKline plc 12.1% Potential Upside Indicated by Berenberg (NYSE:GSK) - February 23 at 5:32 PM
News IconKeybank National Association OH Has $3949000 Position in GlaxoSmithKline PLC (GSK) (NYSE:GSK) - February 23 at 5:32 PM
News IconGlaxoSmithKline plc (GSK) Price Target Raised to GBX 1800 (NYSE:GSK) - February 23 at 5:32 PM
News IconGlaxoSmithKline PLC (gsk) To Go Ex-Dividend on February 22nd (NYSE:GSK) - February 23 at 5:32 PM logoPositive Results for Relvar® Ellipta® Lung Function Study in Patients with Well-Controlled Asthma (NYSE:GSK) - February 23 at 5:32 PM logoChina updates key drug list in boost for Big Pharma (NYSE:GSK) - February 23 at 4:04 AM
News IconGlaxoSmithKline Consumer Nigeria PLC GLAXOSMITH Financial and Strategic SWOT Analysis Review [Updated: 13012017] Prices from USD $300 (NYSE:GSK) - February 22 at 6:02 PM logoPfizer's Leukemia Candidate Gets Priority Review in U.S. (NYSE:GSK) - February 22 at 6:02 PM logoBiotech: What's Next For Gilead, Glaxo, and Merck HIV Treatments (NYSE:GSK) - February 22 at 1:01 PM
News IconWhat Analysts Report Shows About GlaxoSmithKline PLC (NYSE:GSK)? - Transcript Daily (NYSE:GSK) - February 18 at 5:05 PM logo2 High-Yield Dividend Stocks That Are Ridiculously Cheap (NYSE:GSK) - February 18 at 12:20 PM logoShire (SHPG) Beats on Q4 Earnings, Sales; Gives Upbeat View (NYSE:GSK) - February 17 at 4:07 PM logoDrugs-crazed shoot-out: which investment is best out of Astra, Glaxo and Shire? (NYSE:GSK) - February 17 at 8:45 AM
News IconGlaxoSmithKline PLC (LON:GSK) Receives Buy Rating From Jefferies International Analysts (NYSE:GSK) - February 17 at 8:45 AM
News IconGlaxoSmithKline plc (GSK) recently sold by insider GLAXOSMITHKLINE PLC (NYSE:GSK) - February 16 at 5:29 PM logoAnalyst Activity – Beaufort Securities Reiterates Buy on GlaxoSmithKline plc (LON:GSK) (NYSE:GSK) - February 16 at 5:28 PM
News IconThe Regentatlantic Capital LLC Has $222000 Position in GlaxoSmithKline PLC (GSK) (NYSE:GSK) - February 16 at 5:28 PM
News IconGlaxoSmithKline plc (NYSE:GSK) Stock current Trends Analysis (NYSE:GSK) - February 16 at 5:28 PM logoGlaxoSmithKline’s HIV Business in 4Q16 (NYSE:GSK) - February 16 at 5:28 PM logoGlaxoSmithKline’s Vaccines Business Reported Growth in 4Q16 (NYSE:GSK) - February 16 at 5:28 PM logoGlaxoSmithKline’s Consumer Healthcare Reports Growth in 4Q16 (NYSE:GSK) - February 16 at 5:28 PM logoZoetis (ZTS) Beats Q4 Earnings Estimates, Lowers Outlook (NYSE:GSK) - February 16 at 5:28 PM logo4Q16 Performance of GlaxoSmithKline’s Business Segments (NYSE:GSK) - February 14 at 6:46 PM logoPerformance of GlaxoSmithKline’s Pharmaceuticals Segment in 4Q16 (NYSE:GSK) - February 14 at 6:46 PM logoETFs with exposure to GlaxoSmithKline Plc : February 14, 2017 (NYSE:GSK) - February 14 at 6:45 PM
News IconGlaxoSmithKline PLC (ADR) (GSK) Two-Drug Cocktail Aims Decrease HIV Patient Pill Intake (NYSE:GSK) - February 14 at 1:24 PM logoGSK: ViiV Healthcare Shows Positive Study Results For Two-drug Regimen For HIV (NYSE:GSK) - February 14 at 4:32 AM logoGlaxoSmithKline : *JPMORGAN RAISES GLAXOSMITHKLINE PRICE TARGET TO 1670 PENCE - 'NEUTRAL' (NYSE:GSK) - February 13 at 11:39 AM logoDon’t take 1.15% from Premium Bonds when these 2 income stocks pay over 5% (NYSE:GSK) - February 13 at 11:39 AM logoGlaxoSmithKline Plc :GSK-US: Earnings Analysis: 2016 By the Numbers : February 13, 2017 (NYSE:GSK) - February 13 at 11:39 AM
News IconMost Recent analysts Ratings: GlaxoSmithKline plc (NYSE:GSK) (NYSE:GSK) - February 12 at 5:28 PM
News IconThe Wrapmanager Inc. Sells 17089 Shares of GlaxoSmithKline PLC (GSK) (NYSE:GSK) - February 12 at 5:28 PM
News IconGlaxoSmithKline plc 8.4% Potential Upside Indicated by Deutsche Bank (NYSE:GSK) - February 12 at 5:28 PM
News IconStock for Your Case: GlaxoSmithKline plc (NYSE:GSK) (NYSE:GSK) - February 12 at 5:28 PM logoGilead Sciences, Inc. (NASDAQ:GILD), GlaxoSmithKline Plc (NYSE:GSK) Battle Head-On In HIV Treatment - Market Exclusive (NYSE:GSK) - February 11 at 4:15 AM logoGlaxoSmithKline Plc :GSK-US: Earnings Analysis: Q4, 2016 By the Numbers : February 10, 2017 (NYSE:GSK) - February 10 at 6:13 PM
News IconThe Zero Preference Growth Trust PLC, The's (ZPG) " Neutral" Rating Reaffirmed at Macquarie (NYSE:GSK) - February 9 at 6:24 PM
News IconThe GlaxoSmithKline PLC (GSK) Stake Maintained by Botty Investors LLC (NYSE:GSK) - February 9 at 6:24 PM
News IconAnalysts At Liberum Capital Reiterated GlaxoSmithKline PLC (LON:GSK) As Buy (NYSE:GSK) - February 9 at 6:24 PM logoGilead, GlaxoSmithKline Race for HIV Cure (GILD,GSK) (NYSE:GSK) - February 9 at 6:23 PM logoGlaxoSmithKline and Gilead to face off at HIV meeting next week (NYSE:GSK) - February 8 at 11:13 PM logo[$$] GlaxoSmithKline Warns of Hit From Advair Copycat (NYSE:GSK) - February 8 at 11:13 PM logoVaccine Sales Help GSK Results, Shares Up (NYSE:GSK) - February 8 at 11:13 PM logoGilead: Where's the Bottom? (NYSE:GSK) - February 8 at 11:13 PM


What is GlaxoSmithKline PLC's stock symbol?

GlaxoSmithKline PLC trades on the New York Stock Exchange (NYSE) under the ticker symbol "GSK."

How often does GlaxoSmithKline PLC pay dividends? What is the dividend yield for GlaxoSmithKline PLC?

GlaxoSmithKline PLC announced a quarterly dividend on Wednesday, February 8th. Stockholders of record on Friday, February 24th will be paid a dividend of $0.571 per share on Thursday, April 13th. This represents a $2.28 dividend on an annualized basis and a dividend yield of 5.50%. The ex-dividend date is Wednesday, February 22nd. This is a boost from GlaxoSmithKline PLC's previous quarterly dividend of $0.46.

Where is GlaxoSmithKline PLC's stock going? Where will GlaxoSmithKline PLC's stock price be in 2017?

16 brokers have issued twelve-month price targets for GlaxoSmithKline PLC's stock. Their forecasts range from $50.00 to $50.00. On average, they expect GlaxoSmithKline PLC's stock price to reach $50.00 in the next year.

When will GlaxoSmithKline PLC announce their earnings?

GlaxoSmithKline PLC is scheduled to release their next quarterly earnings announcement on Wednesday, February, 1st 2017.

Who owns GlaxoSmithKline PLC stock?

GlaxoSmithKline PLC's stock is owned by many different of institutional and retail investors. Top institutional investors include FMR LLC (0.87%), State Street Corp (0.44%), Hotchkis & Wiley Capital Management LLC (0.32%), Federated Investors Inc. PA (0.15%), Renaissance Technologies LLC (0.13%) and Two Sigma Investments LP (0.12%).

Who sold GlaxoSmithKline PLC stock? Who is selling GlaxoSmithKline PLC stock?

GlaxoSmithKline PLC's stock was sold by a variety of institutional investors in the last quarter, including Federated Investors Inc. PA, O Shaughnessy Asset Management LLC, Hotchkis & Wiley Capital Management LLC, Osterweis Capital Management Inc., FMR LLC, Thornburg Investment Management Inc., NWQ Investment Management Company LLC and Envestnet Asset Management Inc..

Who bought GlaxoSmithKline PLC stock? Who is buying GlaxoSmithKline PLC stock?

GlaxoSmithKline PLC's stock was acquired by a variety of institutional investors in the last quarter, including Equity Investment Corp Acquisition Inc, Renaissance Technologies LLC, Two Sigma Investments LP, Paulson & CO. Inc., Marshall Wace LLP, State Street Corp, Jarislowsky Fraser Ltd and Van ECK Associates Corp.

How do I buy GlaxoSmithKline PLC stock?

Shares of GlaxoSmithKline PLC can be purchased through any online brokerage account. Popular online brokerages include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.

How much does a share of GlaxoSmithKline PLC stock cost?

One share of GlaxoSmithKline PLC stock can currently be purchased for approximately $41.56.

GlaxoSmithKline PLC (NYSE:GSK) Chart for Saturday, February, 25, 2017

Institutional Ownership Chart

Institutional Ownership by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Earnings History Chart

Earnings by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Dividend History Chart

Dividend Payments by Quarter for GlaxoSmithKline PLC (NYSE:GSK)

Last Updated on 2/25/2017 by Staff